- Email: [email protected]
Cranfield University creates water business
NEWS Editorial Office: Elsevier Advanced Technology, P O Box 150, Kidlington Oxford OX5 1AS, UK Tel: +44 (0)1865 843239 Fax: +44 (0)1865 843971 E-mail: [email protected]
Editor: Steve Barrett
Contributing Editor: Simon Atkinson Tel/Fax: +44 (0)1608 641631 E-mail: [email protected]
Production Coordinator: Ben Pelling Editorial advisory board: Dr P Ball (Pall Europe), Dr D Bessarabov (Kvaerner Chemetics, A Division of Kvaerner Canada Inc, Canada), Prof. M Cheryan (University of Illinois at Urbana-Champaign), Prof. A Fane (University of New South Wales), Dr T Franken (Membrane Application Centre Twente), Dr E Gobina (Robert Gordon University), Dr A Merry (PCI Membrane Systems), Prof. M Nyström (Lappeenranta University of Technology), Dr G Pearce (Kalsep), Dr P Pfromm (Institute of Paper Science & Technology, GA, USA), Dr R Philpott (Whatman International), Dr A Turner (AEA Technology), Prof. R Wakeman (Loughborough University of Technology), Prof. A Yaroshchuk (Ukrainian Academy of Sciences). Permissions may be sought directly from Elsevier Rights & Permissions Department, PO Box 800, Oxford OX5 1DX, UK; tel: +44 (0)1865 843830, fax: +44 (0)1865 853333, e-mail: permissions@ elsevier.com. You may also contact Rights & Permissions directly through Elsevier’s home page (http://www.elsevier.com), selecting first ‘Customer Support’, then ‘General Information’, then ‘Permissions Query Form’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc, 222 Rosewood Drive, Danvers, MA 01923, USA; tel: 978 7508400, fax: +1 978 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; tel: +44 (0) 171 436 5931; fax: +44 (0)171 436 3986. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution. Permission of the publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Contact the publisher at the address indicated. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher. Address permissions requests to: Elsevier Rights & Permissions Department, at the mail, fax and e-mail addresses noted above. Notice No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
02095 Printed by Mayfield Press (Oxford) Ltd.
2
Cranfield University creates water business A new water business has just completed a successful spin-out from the School of Water Sciences at Cranfield University in the UK. According to its Technical Director, Professor Tom Stephenson, the new company – called Water Innovate Ltd – will break new ground by providing, for the first time, an effective conduit for the transfer of new technologies out of the laboratory and into the water industry. He says that it will bridge the innovation gap that has existed in the water sector for far too long. John Catling, former Managing Director of Thames Water’s Products Division, joined the company as Executive Chairman, after leading a consortium of investors to fund technical developments and bring them to the market as commercial products. Catling says that investors were not only looking for leading-edge technology with clear market potential, but they also wanted a proven management team that knew the sector and had a successful track record. Dr Steve Callister, who has 15 years of business development experience with both water and wastewater process technology firms, joins the company as Managing Director. Among the technologies on which Water Innovate is initially focusing are an odor modeling software package, and a nitrification toxicity monitoring technique. The software, called OdourSim, dynamically predicts the generation and emission of odors from sewage treatment works, allowing more accurate dispersion contour plots to be generated. N-Tox monitors the condition of a wastewater treatment plant and provides an early warning of equipment failure. The company is also offering a chemical additive for water and wastewater treatment, and three tertiary process technologies for wastewater treatment. Dr Steve Callister explains Water Innovate’s strategy: ‘Our
initial focus is on commercializing the first three technologies, and taking them to market either directly or through licensing deals. We will also be investing significant resources in further development of the remaining technologies, as well as in evaluating opportunities to acquire additional portfolios of water-related technology to bring to market.’ Water Innovate’s funding has been provided by the National Endowment for Science, Technology and the Arts, Oxford Technology 4 Venture Capital Trust, Cranfield Enterprises Ltd, a group of private investors, and the company’s management. Contacts: Cranfield University, School of Water Sciences, School of Industrial & Manufacturing Science, Cranfield, Bedfordshire MK43 0AL, UK. Tel: +44 1234 750111, www.cranfield.ac.uk/sims/water Steve Callister, Water Innovate Ltd, UK. Tel: +44 7879 870741, Email: [email protected], www.waterinnovate.co.uk
Pall sees thirdquarter sales rise by 6.5% US-based Pall Corporation’s sales for its third quarter to 30 April 2005 increased by 6.5%, to $493.5 million. For the corresponding period of 2004 the company reported sales of $463.9 million. The company, which is based in East Hills, New York, also reported earnings of $43.7 million ($0.35 per share), compared with $46.5 million (US$0.37 per share) for a year earlier. Excluding restructuring and other charges, net of related tax effect, earnings on a pro forma basis totalled $46.3 million ($0.37 per share), compared with the $47 million ($0.37 per share) recorded for the third quarter of 2004. Restructuring and other charges of approximately $4.3 million were recorded in this quarter. These costs relate mainly to the company’s CoRe cost reduction program and business restructuring along with the write-down of a
strategic investment during the first quarter. ‘The far-reaching realignment of our business is nearing completion,’ comments Eric Krasnoff, the company’s Chairman and Chief Executive Officer. ‘We can already see one of its key objectives, spurring top-line growth, starting to show through in the quarter and nine-month results. Our earnings are stable, and now expected to ramp up more in line with our long-term goals starting next fiscal year.’ Industrial sales grew by 3.5% in the quarter — with an operating profit margin of 14.2%, at a strong $41.5 million. Microelectronics sales dropped by 10.5% compared with the equivalent quarter of 2004. This was caused by the cyclical nature of the end-market. The company says that the forecast downturn in the Microelectronics segment was steeper than expected in the large Asian market place. For the quarter, the operating profit margin for this segment was 14.6%. Life Sciences’ sales increased by 2% for the third quarter, as strong growth in BioPharmaceuticals was offset by a shortfall in the Medical portion of the business. Life Sciences’ operating profit margin, at 21.6%, was on a par with that of the corresponding period a year earlier, while operating profit rose by 5% to $43.6 million. Contact: Pall Corporation, 2200 Northern Boulevard, East Hills, NY 11548, USA. Tel: +1 516 484 5400, www.pall.com
Profos extends EndoTrap product portfolio The German biotechnology firm Profos AG has added ‘EndoTrap red’ to its portfolio of products that are used to remove endotoxins from biopharmaceutical products. EndoTrap is based on Profos’s patented technology, and the new product joins the firm’s exisiting ‘EndoTrap blue’. EndoTrap is described as a highly affine chromatographic purification system for protein solutions.
Membrane Technology July 2005
Editor: Steve Barrett
Contributing Editor: Simon Atkinson Tel/Fax: +44 (0)1608 641631 E-mail: [email protected]
Production Coordinator: Ben Pelling Editorial advisory board: Dr P Ball (Pall Europe), Dr D Bessarabov (Kvaerner Chemetics, A Division of Kvaerner Canada Inc, Canada), Prof. M Cheryan (University of Illinois at Urbana-Champaign), Prof. A Fane (University of New South Wales), Dr T Franken (Membrane Application Centre Twente), Dr E Gobina (Robert Gordon University), Dr A Merry (PCI Membrane Systems), Prof. M Nyström (Lappeenranta University of Technology), Dr G Pearce (Kalsep), Dr P Pfromm (Institute of Paper Science & Technology, GA, USA), Dr R Philpott (Whatman International), Dr A Turner (AEA Technology), Prof. R Wakeman (Loughborough University of Technology), Prof. A Yaroshchuk (Ukrainian Academy of Sciences). Permissions may be sought directly from Elsevier Rights & Permissions Department, PO Box 800, Oxford OX5 1DX, UK; tel: +44 (0)1865 843830, fax: +44 (0)1865 853333, e-mail: permissions@ elsevier.com. You may also contact Rights & Permissions directly through Elsevier’s home page (http://www.elsevier.com), selecting first ‘Customer Support’, then ‘General Information’, then ‘Permissions Query Form’. In the USA, users may clear permissions and make payments through the Copyright Clearance Center, Inc, 222 Rosewood Drive, Danvers, MA 01923, USA; tel: 978 7508400, fax: +1 978 7504744, and in the UK through the Copyright Licensing Agency Rapid Clearance Service (CLARCS), 90 Tottenham Court Road, London W1P 0LP, UK; tel: +44 (0) 171 436 5931; fax: +44 (0)171 436 3986. Other countries may have a local reprographic rights agency for payments. Derivative Works Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. Permission of the publisher is required for resale or distribution outside the institution. Permission of the publisher is required for all other derivative works, including compilations and translations. Electronic Storage or Usage Permission of the publisher is required to store or use electronically any material contained in this journal, including any article or part of an article. Contact the publisher at the address indicated. Except as outlined above, no part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the publisher. Address permissions requests to: Elsevier Rights & Permissions Department, at the mail, fax and e-mail addresses noted above. Notice No responsibility is assumed by the publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. Although all advertising material is expected to conform to ethical (medical) standards, inclusion in this publication does not constitute a guarantee or endorsement of the quality or value of such product or of the claims made of it by its manufacturer.
02095 Printed by Mayfield Press (Oxford) Ltd.
2
Cranfield University creates water business A new water business has just completed a successful spin-out from the School of Water Sciences at Cranfield University in the UK. According to its Technical Director, Professor Tom Stephenson, the new company – called Water Innovate Ltd – will break new ground by providing, for the first time, an effective conduit for the transfer of new technologies out of the laboratory and into the water industry. He says that it will bridge the innovation gap that has existed in the water sector for far too long. John Catling, former Managing Director of Thames Water’s Products Division, joined the company as Executive Chairman, after leading a consortium of investors to fund technical developments and bring them to the market as commercial products. Catling says that investors were not only looking for leading-edge technology with clear market potential, but they also wanted a proven management team that knew the sector and had a successful track record. Dr Steve Callister, who has 15 years of business development experience with both water and wastewater process technology firms, joins the company as Managing Director. Among the technologies on which Water Innovate is initially focusing are an odor modeling software package, and a nitrification toxicity monitoring technique. The software, called OdourSim, dynamically predicts the generation and emission of odors from sewage treatment works, allowing more accurate dispersion contour plots to be generated. N-Tox monitors the condition of a wastewater treatment plant and provides an early warning of equipment failure. The company is also offering a chemical additive for water and wastewater treatment, and three tertiary process technologies for wastewater treatment. Dr Steve Callister explains Water Innovate’s strategy: ‘Our
initial focus is on commercializing the first three technologies, and taking them to market either directly or through licensing deals. We will also be investing significant resources in further development of the remaining technologies, as well as in evaluating opportunities to acquire additional portfolios of water-related technology to bring to market.’ Water Innovate’s funding has been provided by the National Endowment for Science, Technology and the Arts, Oxford Technology 4 Venture Capital Trust, Cranfield Enterprises Ltd, a group of private investors, and the company’s management. Contacts: Cranfield University, School of Water Sciences, School of Industrial & Manufacturing Science, Cranfield, Bedfordshire MK43 0AL, UK. Tel: +44 1234 750111, www.cranfield.ac.uk/sims/water Steve Callister, Water Innovate Ltd, UK. Tel: +44 7879 870741, Email: [email protected], www.waterinnovate.co.uk
Pall sees thirdquarter sales rise by 6.5% US-based Pall Corporation’s sales for its third quarter to 30 April 2005 increased by 6.5%, to $493.5 million. For the corresponding period of 2004 the company reported sales of $463.9 million. The company, which is based in East Hills, New York, also reported earnings of $43.7 million ($0.35 per share), compared with $46.5 million (US$0.37 per share) for a year earlier. Excluding restructuring and other charges, net of related tax effect, earnings on a pro forma basis totalled $46.3 million ($0.37 per share), compared with the $47 million ($0.37 per share) recorded for the third quarter of 2004. Restructuring and other charges of approximately $4.3 million were recorded in this quarter. These costs relate mainly to the company’s CoRe cost reduction program and business restructuring along with the write-down of a
strategic investment during the first quarter. ‘The far-reaching realignment of our business is nearing completion,’ comments Eric Krasnoff, the company’s Chairman and Chief Executive Officer. ‘We can already see one of its key objectives, spurring top-line growth, starting to show through in the quarter and nine-month results. Our earnings are stable, and now expected to ramp up more in line with our long-term goals starting next fiscal year.’ Industrial sales grew by 3.5% in the quarter — with an operating profit margin of 14.2%, at a strong $41.5 million. Microelectronics sales dropped by 10.5% compared with the equivalent quarter of 2004. This was caused by the cyclical nature of the end-market. The company says that the forecast downturn in the Microelectronics segment was steeper than expected in the large Asian market place. For the quarter, the operating profit margin for this segment was 14.6%. Life Sciences’ sales increased by 2% for the third quarter, as strong growth in BioPharmaceuticals was offset by a shortfall in the Medical portion of the business. Life Sciences’ operating profit margin, at 21.6%, was on a par with that of the corresponding period a year earlier, while operating profit rose by 5% to $43.6 million. Contact: Pall Corporation, 2200 Northern Boulevard, East Hills, NY 11548, USA. Tel: +1 516 484 5400, www.pall.com
Profos extends EndoTrap product portfolio The German biotechnology firm Profos AG has added ‘EndoTrap red’ to its portfolio of products that are used to remove endotoxins from biopharmaceutical products. EndoTrap is based on Profos’s patented technology, and the new product joins the firm’s exisiting ‘EndoTrap blue’. EndoTrap is described as a highly affine chromatographic purification system for protein solutions.
Membrane Technology July 2005